The total production volume of finished medicinal products (FMPs) in Russia by the end of 2025 amounted to RUB 999 billion (in manufacturer selling prices, including VAT). The growth rate compared to the same period in 2024, calculated in Russian currency, reached 15.7%. According to the database "Production of Medicinal Products in Russia" from the analytical company RNC Pharma, in 2025, pharmaceutical companies localized in Russia released approximately 4.03 billion packages of FMPs into circulation, equivalent to 85.1 billion minimum dosage units (MDU). Compared to 2024, drug production decreased by 2% in packages but increased by 2.5% in MDU, as manufacturers consistently shift their focus towards producing larger consumer packages.

Towards the end of the year, the activity of pharmaceutical manufacturers typically increases as companies prepare for the January holidays. In December 2025, pharmaceutical companies localized in our country released a total of approximately 422.3 million packages of finished medicinal products, or 8.61 billion MDU, into circulation. This represents the maximum monthly production volume recorded over several years. Similar figures were only observed in March 2022, when manufacturers released over 442.6 million packages, equivalent to 8 billion MDU. The monetary value of FMP shipments in December 2025 exceeded RUB 100.8 billion, an 11.3% increase compared to the same month a year earlier.

In total, for 2025, the highest production growth rates among major drug groups were observed for antirheumatic drugs and topical analgesics (group M02A), as well as standard solutions (group K01B) — their output increased by 25% and 24% in packages, respectively, compared to 2024.

Within the TOP-30 brands of Rx drugs, leading in terms of physical production volume, most demonstrated significant growth in shipments. Among them, the highest growth rate was exhibited by the diuretic Spironolactone, which was manufactured by four domestic companies during the reporting period, the key one being Ozon Pharmacevtika. Compared to 2024, the total production volume of the drug increased by 92% in packages. Drugs for treating diabetes mellitus, such as Gliclazide, Forsiga, and Metformin, also showed high production growth. The production dynamics for these brands in 2025 ranged from 46% to 82%.

Among the TOP-30 over-the-counter (OTC) brands, the highest growth was shown by the brand "Ant Alcohol" (Muravinyi spirt). Over the year, its production volume tripled, with the growth primarily driven by the activities of the companies NIIMIS and Genel. Most likely, the drug is being consumed off-label, serving as an alternative to alcoholic beverages. Also noteworthy is Furacilin, manufactured by 15 companies, with the main producer being Avexima. The growth rate for this brand was recorded at +39% compared to 2024.

Within the top thirty, a reduction in production was demonstrated by Activated Charcoal. Over the year, its production volume decreased by 53% in packages and 42% in MDU. In the past year, only three manufacturers of this drug were recorded; the main producer of charcoal, Pharmstandard, halved its production output over the year.

Fig. Production Volume of Finished Medicinal Products in Russia (including the output of foreign pharmaceutical companies at their own and contract sites) in 2018–2025, in physical terms (packages) and monetary terms (RUB, including VAT)